Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 465-473

  Mezei, Zsolt ^a   Bereczki, Daniel ^a,b   Racz, Lilla ^a   Csiba, Laszlo ^a   Csepany, Tünde ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

EDSS; Immunomodulatory; Multiple sclerosis; Relapse; Response

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ANXIETY; ARTICLE; CHEST TIGHTNESS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLU LIKE SYNDROME; HEART PALPITATION; HUMAN; HUNGARY; IMMUNOMODULATION; INJECTION SITE REACTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDY; SIDE EFFECT; SKIN NECROSIS;

EID: 84869227890     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S36771     Document Type: Article

References (41)

1. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci. 1987;14:255-261.
2. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin. 1995;13:119-146.
3. [No authors listed]. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:655-661.
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III. multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45: 1268-1276.
5. Jacobs LD, Cookfair D, Rudick R, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
6. [No authors listed]. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998; 352:1498-1504.
7. [No authors listed]. Interferon beta-1b in the treatment of multiple sclerosis: fnal outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45:1277-1285.
8. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67:944-953.
9. Johnson KP, Ford CC, Lisak R P, Wolinsky JS. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand. 2005;111:42-47.
10. Sorensen PS, Koch-Henriksen N, Ravnborg M, et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler. 2006;12:253-264.
11. [No authors listed]. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1994;44:1537-1540.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33: 1444-1452.
14. Syed RA, Mark AA. Current approved options for treating patients with multiple sclerosis. Neurology. 2004;63:S8-S14.
15. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology. 1994;44: 16-20.
16. Bencsik K, Fuvesi J, Fricska-Nagy Z, et al. Short communication: treatment of relapsing-remitting multiple sclerosis patients with IFN-beta1b: results of a 6-year follow-up. J Interferon Cytokine Res. 2006;26: 96-100.
17. Limmroth V, Malessa R, Zettl UK, et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol. 2007;254:67-77.
18. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE trial. Neurology. 2002;59:1496-1506.
19. Freedman MS. Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology. 2011;76:S26-S34.
20. Kremenchutzky M, Rice G P, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129:584-594.
21. Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry. 2003;74:1689-1692.
22. Miralles AA, Fuentes B, Barreiro P, Diez-Tejedor E. Comparative clinical effcacy analysis between interferon beta 1-b and interferon beta 1-a. J Neurol. 2000;247:III139.
23. Öztekin N, Öztekin M F. An open-label trial comparing the effects of IFNß-1a (Rebif), (Avonex), and IFNß-1b (Betaferon) on the relapse rate, lesion load on MRI and disease progression in patients with relapsing-remitting multiple sclerosis: results of 24 months of therapy. Mult Scler. 2001;7:S96.
24. Trojano M, Liguori M, Paolicelli D, et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler. 2003;9:451-457.
25. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903-914.
26. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodula-tory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neur. 2005;12:425-431.
27. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1b for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453-1460.
28. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a frst demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898-904.
29. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays defnite multiple sclerosis 5 years after a frst demyelinating event. Neurolog y. 2006;66:678-684.
30. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to defnite multiple sclerosis: a randomised study. Lancet. 2001;357:1576-1582.
31. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically defnite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67: 1242-1249.
32. Beiske AG, Myhr KM. Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis. J Neurol. 2006;253:377-378.
33. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg. 2006;108:327-332.
34. Hutchinson M. Predicting and preventing the future: actively managing multiple sclerosis. Pract Neurol. 2009;9:133-143, discussion 144.
35. Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally effcacious? A comparative review of open-label studies evaluating the effcacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord. 2011;4: 281-296.
36. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2003;61: 184-189.
37. Río J, Nos C, Tintoré M, et al. Defning the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006;59: 344-352.
38. Pozzili C, Prosperini L. Clinical markers of therapeutic response to disease modifying drugs. Neurol Sci. 2008;29:S211-S213.
39. Río J, Castilló J, Rovira A, et al. Measures in the frst year of therapy predict the response to interferon {beta} in MS. Mult Scler. 2009;15: 848-853.
40. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol. 2009;16:1202-1209.
41. Créange A, Debouverie M, Jaillon-Rivière V, et al. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks. Mult Scler. 2009;15:1085-1091.